A R Zolopa
Affiliation: Stanford University
- HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failedA R Zolopa
Division of Infectious Diseases and Geographical Medicine, Stanford University School of Medicine, CA 94305, USA
Ann Intern Med 131:813-21. 1999..Tests for resistance to HIV drugs are available for clinical use; however, their predictive value has not been fully assessed...
- Incorporating drug-resistance measurements into the clinical management of HIV-1 infectionAndrew R Zolopa
Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
J Infect Dis 194:S59-64. 2006..Finally, newer indicators, such as replication capacity, are clinically available and appear to have prognostic value, but how this in vitro measure should be used in the management of antiretroviral therapy remains to be fully defined...
- Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)Andrew R Zolopa
Stanford University School of Medicine, Stanford, CA 94305 5107, USA
Clin Infect Dis 41:92-9. 2005..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
- Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trialAndrew Zolopa
Stanford University AIDS Clinical Trials Unit, Stanford University, Stanford, California, United States of America
PLoS ONE 4:e5575. 2009..Optimal timing of ART initiation for individuals presenting with AIDS-related OIs has not been defined...
- The evolution of HIV treatment guidelines: current state-of-the-art of ARTAndrew R Zolopa
Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA 94305, USA
Antiviral Res 85:241-4. 2010..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010...
- Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trialAndrew R Zolopa
Div of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Dr, Rm S 156 GrantBldg, Stanford, CA 94305, USA
J Infect Dis 201:814-22. 2010....
- Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic responseN S Shulman
Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
J Acquir Immune Defic Syndr 23:221-6. 2000..To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy...
- High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patientsR W Shafer
Division of Infectious Diseases and Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305, USA
J Clin Microbiol 39:1522-9. 2001....
- Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapyN Shulman
Stanford University School of Medicine, Stanford, CA 94305, USA
AIDS 15:1125-32. 2001..A reversal of phenotypic resistance was seen in patients with NNRTI mutations in the presence of multiple NRTI mutations, but no obvious virologic benefit of this phenomenon was seen in this study...
- Genotypic correlates of a virologic response to stavudine after zidovudine monotherapyN S Shulman
Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
J Acquir Immune Defic Syndr 27:377-80. 2001..We conclude that in patients with prior ZDV treatment, those with only one ZDV mutation, particularly at position 70, can still get reasonable virologic activity from d4T. Those with more mutations are not likely to have much benefit...
- High levels of adherence do not prevent accumulation of HIV drug resistance mutationsDavid R Bangsberg
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, California, USA
AIDS 17:1925-32. 2003..Exceptionally high levels of adherence will not prevent population levels of drug resistance...
- Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative studyM Holodniy
AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, USA
Int J STD AIDS 15:543-51. 2004....
- Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scoresPhilip Grant
Stanford University, Palo Alto, California, USA
Antimicrob Agents Chemother 52:4050-6. 2008....
- Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant
Stanford University, Palo Alto, California, United States of America
PLoS ONE 5:e11416. 2010..However, few studies are prospective, and no study has evaluated the impact of the timing of ART when allocated randomly during an acute opportunistic infection (OI)...
- Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitorPhilip Grant
Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, California 94305 5107, USA
Clin Infect Dis 48:680-2. 2009....
- Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to losePhilip Grant
Division of Infectious Diseases and Geographic Medicine, 300 Pasteur Drive, Room S 101, Stanford, CA 94305 5107, USA
Curr HIV/AIDS Rep 6:63-7. 2009..Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management...
- HIV-1 protease mutations and protease inhibitor cross-resistanceSoo Yon Rhee
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA
Antimicrob Agents Chemother 54:4253-61. 2010....
- Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysisEran Bendavid
Division of General Internal Medicine, Stanford University, Stanford, USA
AIDS 25:211-20. 2011..the World Health Organization (WHO) recently changed its first-line antiretroviral treatment guidelines in resource-limited settings. The cost-effectiveness of the new guidelines is unknown...
- Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremiaNancy Shulman
Stanford University School of Medicine, California, USA
Antimicrob Agents Chemother 46:3907-16. 2002..The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response...
- Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART eraLeslie Cockerham
Department of Medicine, University of California, San Francisco, CA, USA
J Acquir Immune Defic Syndr 53:102-6. 2010..To determine the relationship of HIV infection, demographic, and cardiovascular disease (CVD) risk factors with mortality in the recent highly active antiretroviral therapy era...
- Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individualsPhyllis C Tien
Department of Medicine, University of California, San Francisco, CA 94121, USA
J Acquir Immune Defic Syndr 48:169-76. 2008..Obesity is associated with hepatic steatosis, and ALT is a marker of steatosis in the general population...
- Regional adipose tissue and lipid and lipoprotein levels in HIV-infected womenJudith Currier
Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
J Acquir Immune Defic Syndr 48:35-43. 2008..HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional body fat and lipid levels is not well described...
- Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatmentsThomas D Wu
Department of Biochemistry, Stanford University, Stanford, California 94305, USA
J Virol 77:4836-47. 2003..The presence of mutational clusters provides insight into the complex mutational patterns required for HIV-1 protease inhibitor resistance...
- HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceSoo-Yon Rhee
Division of Infectious Diseases, Department of Medicine, Stanford University, CA 94301, USA
J Infect Dis 192:456-65. 2005..In contrast, nonpolymorphic treatment-associated mutations may be more sensitive and specific markers of transmitted HIV-1 drug resistance...
- Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitorsMatthew J Gonzales
Division of Infectious Diseases, Department of Medicine, Stanford University, CA, USA
AIDS 17:791-9. 2003..Most NRTI mutations group into one of three clusters, although several (e.g., M184V) occur in multiple mutational contexts...
- Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman
Stanford University School of Medicine, California 94305, USA
J Acquir Immune Defic Syndr 31:121-7. 2002..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
- Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapyRami Kantor
Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94301, USA
Antimicrob Agents Chemother 46:1086-92. 2002..The persistence of L90M, V82A/F/T, G48V, and I84V during salvage therapy suggests that these mutations play a role in clinical resistance to multiple PIs...
- Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistanceAndrew R Zolopa
AIDS 17:1077-8. 2003
- Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observationMatthew J Gonzales
Department of Medicine/Division of Infectious Diseases, Stanford University, Stanford, USA
J Infect Dis 188:397-405. 2003..Although HIV-1 PR and RT genes from treated persons may become highly divergent, these changes usually are the result of sequence evolution, rather than superinfection...
- Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapineDenise Lecossier
INSERM U552, , Paris, France
J Acquir Immune Defic Syndr 38:37-42. 2005..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...
- N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failureYumi Mitsuya
Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA
AIDS Res Hum Retroviruses 22:1300-5. 2006....
- Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell
Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
Clin Infect Dis 41:236-42. 2005..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
- Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta
University of Alabama at Birmingham, Birmingham, Alabama, USA
Antimicrob Agents Chemother 51:3104-10. 2007..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
- Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meetMinghsun Liu
Division of Infectious Diseases, Stanford University Medical Center, Stanford, California, USA
MedGenMed 8:24. 2006
- The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsPhyllis C Tien
Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, CA, USA
Am J Epidemiol 163:860-9. 2006..The representativeness of the FRAM sample increases its value as a resource for studies on fat distribution, metabolic changes, and atherosclerosis in HIV infection...
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Pharmacol Ther 78:143-53. 2005..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
- Stanford AIDS Clinical Trials UnitAndrew Zolopa; Fiscal Year: 2007..Although this working arrangement has been successful for over 10 years, further consolidations and streamlining described here will ensure that the proposed CTU and CRSs will be even more efficient. ADMINISTRATIVE COMPONENT: ..